Zurstrassen CE, Bitencourt AGV, Guimaraes MD, Cavalcante ACBS, Tyng CJ, Amoedo MK, Matsushita Junior JPK, Szklaruk J, Marchiori E, Chojniak R. Percutaneous stent placement for the treatment of malignant biliary obstruction: nitinol versus elgiloy stents.
Radiol Bras 2017;
50:97-102. [PMID:
28428652 PMCID:
PMC5396999 DOI:
10.1590/0100-3984.2015.0183]
[Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
Objective
This study aimed to compare two self-expanding stents, a nitinol stent and an
elgiloy stent, both placed percutaneously, in terms of their efficacy in
palliating inoperable malignant biliary obstruction.
Materials and Methods
We retrospectively investigated 99 patients with unresectable malignant
biliary obstruction treated with percutaneous placement of a self-expanding
metallic stent at our institution between May 2007 and January 2010. Serum
bilirubin and liver enzyme levels were measured before and 30 days after
stenting. For all procedures using elgiloy or nitinol stents, stent
occlusion and patient survival rates were calculated using Kaplan-Meyer
analysis.
Results
All of the patients showed clinical improvement after stent placement, with
no difference between the two groups. In both groups, the occlusion-free
survival rate was 67% at 30 days, 37% at 90 days, 25% at 180 days, and 10%
at 360 days, with no significant difference in relation to the type of
stent.
Conclusion
The two stents evaluated showed comparable efficacy for the percutaneous
treatment of unresectable biliary malignancy, with good clinical
results.
Collapse